News

From Beef to Bots? Harvard Professors Mired in Debate Over Spam Emails, Industry-Funded Research

News

Days Before Deadline, Environmentalist Overseer Campaign Harvard Forward On Track To Reach Nomination Goal

News

Swissbäkers Reopens Allston Location in Light of Recent Closures

News

Harvard Scientists Find Stress Makes Hair Turn Gray

News

The New Gen Ed Lottery System, Explained

Former Harvard Post-Doc Suing University for Patent Royalties

By Akshitha Ramachandran, Crimson Staff Writer

A former Harvard post-doctoral researcher is suing a chemistry professor whose lab he worked in, alleging that the professor unfairly excluded him from a potentially lucrative cancer treatment patent.

Alexander Arefolov—who worked in the laboratory of Matthew D. Shair from 2011 to 2015 and filed the suit on May 4—claims he contributed to research on the compound cortistatin A. After the drug was licensed to Merck &Co. last year, though, Arefolov said his name did not appear on the list of inventors, cutting him out of monetary returns.

According to Arefolov’s complaint, Shair and others listed as inventors on the cortistatin A patents have received almost $6 million in patent royalties, and Harvard received an up-front payment of $20 million.

The post-doc was the only chemist other than Shair working in the lab when he started there, according to the complaint. The lawsuit further alleges that Shair repeatedly reassured Arefolov that he would be recognized on the patent.

“As an integral team member of the Cortistatin A Project for four years, Dr. Arefolov was involved in almost all aspects of the project,” the complaint reads. “Four years of lab notebooks, personal journals, email correspondence, and the testimony of the scientists working on the Cortistatin A Project will bear that out.”

The lawsuit also claims that the University failed to review the work of students and post-docs when determining inventorship—instead, the University allegedly relied on Shair to determine who would be given credit for the invention. Given that Harvard generally requires patent royalties to be shared equally between inventors, the complaint continues, omitting Arefolov from the inventors list could have increased Shair’s slice of the profits.

In a statement to the Boston Globe, University spokesperson David Cameron declined to comment on the lawsuit.

Arefolov’s attorney, Brian D. O’Reilly, previously represented Mark G. Charest, a former Harvard Ph.D. student who filed a similar suit in 2013. After roughly three years, Charest settled with Harvard in the summer of 2016.

—Staff writer Akshitha Ramachandran can be reached at akshitha.ramachandran@thecrimson.com. Follow her on Twitter @aramachandran13.

Want to keep up with breaking news? Subscribe to our email newsletter.

Tags
ResearchChemistry